Amneal Pharmaceuticals, Inc.

AMRX • Drug Manufacturers - Specialty & Generic

$17.44

▼ -0.43 (-2.41%)

Current price

EarningsLatest report: Jun 30, 2026

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$5.72B

Growth

7.9%

Cash Flow

4/5

Trend

Mostly stable

Evidence

Positive free cash flow · 0.86Consistent free cash flow · 4/5Healthy liquidity · 2.17Expensive earnings multiple · 54.8Negative growth trend

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 12:40 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$17.44

Change-2.41%

Shares Out328.10M

Market Cap$5.72B

Enterprise Value$8.26B

52W Range8.01 - 19.26

Beta1.26

P/E36.31

P/S1.84

P/B173.27

P/FCF44.12

EV/Sales2.65

Price$17.44

Change-2.41%

Shares Out328.10M

Market Cap$5.72B

Enterprise Value$8.26B

52W Range8.01 - 19.26

Beta1.26

P/E36.31

P/S1.84

P/B173.27

P/FCF44.12

EV/Sales2.65

EV/EBITDA18.46

EV/FCF63.72

Earnings Yield2.75%

FCF Yield2.27%

Dividend Yield0.00%

Gross Margin37.63%

Oper. Margin14.02%

Profit Margin2.39%

Debt/Eq-38.65

Current Ratio2.17

Quick Ratio1.48

Revenue 5Y7.94%

FCF 5Y15.65%

Target$20.67

Target Upside18.52%

Target Median$21.00

Target Range16.00 - 25.00

Volume1.15M

Avg Volume1.92M

EPS Surprise0.10

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

55/100

Financial Strength

Debt, cash, stability

70/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

69/100

Why this score▼

Positive free cash flow · 0.86Consistent free cash flow · 4/5Healthy liquidity · 2.17Expensive earnings multiple · 54.8Negative growth trend

Analyst view

Analyst sentiment and price target

AMRX

Analyst sentiment

Based on 17 analyst votes · 2026-09-05

82/100

Bullish

Hold

Bearish

Price Target

2026-08-07

Low

$16.00

Mean

$19.75

Median

$19.00

High

$25.00

Company Overview

IPO: 5/7/2018

Industry: Drug Manufacturers - Specialty & Generic

P/B i: 173.27

Debt / Equity i: -38.65

Operating Margin: 14.02%

Net Margin: 2.39%

ROE i: -

ROIC: -

Financial Health

Score14 / 20

Debt / Equity: -38.65

Current Ratio: 2.17

Quick Ratio: 1.48

Status: Good

Insider Transactions

Recent executive and insider activity

Autor Deborah M.

Transaction: 05/11/2026

SELL

Change

-34,819

Price

$12.94

Filing

05/12/2026

Type

SELL

Yanai Shlomo

Transaction: 05/07/2026

SELL

Change

-34,819

Price

Not reported

Filing

05/08/2026

Type

SELL

Yanai Shlomo

Transaction: 05/07/2026

BUY

Change

+34,819

Price

Not reported

Filing

05/08/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Autor Deborah M.	SELL	-34,819	$12.94	05/11/2026	05/12/2026
Yanai Shlomo	SELL	-34,819	Not reported	05/07/2026	05/08/2026
Yanai Shlomo	BUY	+34,819	Not reported	05/07/2026	05/08/2026
MEISTER PAUL M	SELL	-48,747	Not reported	05/07/2026	05/08/2026
MEISTER PAUL M	BUY	+48,747	Not reported	05/07/2026	05/08/2026
Nark Ted C	SELL	-34,819	Not reported	05/07/2026	05/08/2026
Nark Ted C	BUY	+34,819	Not reported	05/07/2026	05/08/2026
Kiely John	SELL	-34,819	Not reported	05/07/2026	05/08/2026
Kiely John	BUY	+34,819	Not reported	05/07/2026	05/08/2026
Patel Gautam	SELL	-34,819	Not reported	05/07/2026	05/08/2026
Patel Gautam	BUY	+34,819	Not reported	05/07/2026	05/08/2026
George Jeffrey P.	SELL	-34,819	Not reported	05/07/2026	05/08/2026
George Jeffrey P.	BUY	+34,819	Not reported	05/07/2026	05/08/2026
Autor Deborah M.	SELL	-34,819	Not reported	05/07/2026	05/08/2026
Autor Deborah M.	BUY	+34,819	Not reported	05/07/2026	05/08/2026
BUCHI J KEVIN	SELL	-34,819	Not reported	05/07/2026	05/08/2026
BUCHI J KEVIN	BUY	+34,819	Not reported	05/07/2026	05/08/2026
Yanai Shlomo	BUY	+19,824	Not reported	05/06/2026	05/08/2026
MEISTER PAUL M	BUY	+30,837	Not reported	05/06/2026	05/08/2026
Nark Ted C	BUY	+19,824	Not reported	05/06/2026	05/08/2026

About the Company

Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.

Source - link

Peers

BHC DYN INDV LNTH MIRM NVST PRGO SLNO SUPN TLX

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low

COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.

Zacks Investment Research

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

Zacks Investment Research

STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)---- $AMRX #AMRX--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company's current shareholders.The investigation seeks to determine whether Amneal or the company's officers and/or directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional informat.

Business Wire

5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns

Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.

Zacks Investment Research

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?

Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.

Zacks Investment Research

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-07	0.17	0.27	0.1
2026-02-27	0.18	0.21	0.03
2025-10-30	0.13	0.17	0.04
2025-08-05	0.18	0.25	0.07
2025-05-02	0.15	0.21	0.06
2025-02-28	0.15	0.12	-0.03
2024-11-08	0.13	0.16	0.03
2024-08-09	0.14	0.16	0.02
2024-05-03	0.09	0.14	0.05
2024-03-01	0.07	0.14	0.07
2023-11-07	0.12	0.19	0.07
2023-08-04	0.1	0.19	0.09